Actually, even if HBV-associated HCCs hold the latter mutations, they are more frequent in HCV-associated HCC (TERT, 60–80% in HCV-HCC vs. 30–40% in HBV-HCC [83,84,85]; ARID2, 18% in HCV-HCC vs. 2% in HBV-HCC [86]). Here, ARID2 is linked to hepatocellular carcinoma.